These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD. Eldem BM; Muftuoglu G; Topbaş S; Çakir M; Kadayifcilar S; Özmert E; Bahçecioğlu H; Sahin F; Sevgi S; Acta Ophthalmol; 2015 Sep; 93(6):e458-64. PubMed ID: 25160859 [TBL] [Abstract][Full Text] [Related]
14. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study. Holz FG; Dugel PU; Weissgerber G; Hamilton R; Silva R; Bandello F; Larsen M; Weichselberger A; Wenzel A; Schmidt A; Escher D; Sararols L; Souied E Ophthalmology; 2016 May; 123(5):1080-9. PubMed ID: 26906165 [TBL] [Abstract][Full Text] [Related]
15. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P; Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215 [TBL] [Abstract][Full Text] [Related]
16. Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Avila MP; Farah ME; Santos A; Carla L; Fuji G; Rossi J; Nau J Retina; 2012 Jan; 32(1):10-8. PubMed ID: 21817963 [TBL] [Abstract][Full Text] [Related]